GlobeNewswire

Khot Shareholders Approve all Resolutions including Change of Name to "Blockchain Holdings Ltd." at its Annual General and Special Meeting

Dela

TORTOLA, British Virgin Islands, April 18, 2018 (GLOBE NEWSWIRE) -- Khot Infrastructure Holdings, Ltd. (the "Company") (CSE:KOT) is delighted to announce at the Company's annual general and special meeting of shareholders held on April 9, 2018 (the "Meeting"), all agenda items and proposals put forward by the Board of Directors, as further described in the Company's information circular dated March 9, 2018, were approved, including the following:

  • Proposed Change of Business from transportation infrastructure in Mongolia to developing proprietary indexes and ancillary data products for emerging blockchain and digital currency markets.
  • Amendment to the Company's articles of incorporation to change the name of the Company to "Blockchain Holdings Ltd."
  • Setting the number of directors of the Company until the next annual general meeting at five.
  • Elected to the board of directors are: James Passin, Executive Chairman, Don Padgett, Jeremy Gardner, Wayne Lloyd and Gregory Kallinikos.   
  • Re-appointment of Dale Matheson Carr-Hilton Labonte LLP ("DMCL LLP") as auditors of the Company for the ensuing financial year and the Director's right to fix the remuneration to be paid to DCML LLP.
  • New rolling 10% Stock Option Plan.
  • Sale of its Mongolian subsidiary, Ashid Munkhiin Zam LLC.
  • Amendment to the articles of the Company to consolidate the outstanding common shares of the Company (the "Consolidation") on the basis of one (1) post-Consolidated common share for every ten (10) pre-Consolidated common shares.  Registered shareholders of the Company received a letter of transmittal containing instructions on how to obtain new share certificates of the Company by mail. The letter of transmittal is posted on SEDAR under the Company's profile at www.sedar.com and is subject to final acceptance from the Canadian Securities Exchange.

Kenneth Farrell resigned from the Company's Board of Directors effective March 15, 2018.  Erin Chutter and Orgilmaa Siizkhuu did not stand for re-election at the Meeting. The Company thanks Mr. Farrell, Ms. Chutter and Ms. Siizkhuu for their contribution during the time of their directorships and wishes them well in their future endeavours.

The Company is also pleased to announce that further to its press release of March 26, 2018, it has completed its non-brokered private placement (the "Private Placement") of subscription receipts (each, a "Receipt") for gross proceeds of $500,000 at a price of $0.10 per Receipt (assuming the completion of the Consolidation). The proceeds of the Private Placement will be held in escrow pending the completion of the transactions approved at the Meeting, whereupon, each Receipt will automatically convert into one common share of the Company, as constituted following completion of the Consolidation.

The Private Placement is subject to regulatory approval, and any securities to be issued pursuant to the Private Placement are subject to a four-month and one day hold period under applicable Canadian securities law.

The proceeds of the Private Placement will be used for the development of proprietary indexes and ancillary data products for emerging blockchain and digital currency markets, and for working capital and general corporate purposes.

The Company confirms that it has reached agreement with its lenders to repay CAD$628,304.68 in debt by the issuance of 6,283,047 common shares of the Company at a price of $0.10 per share (assuming the completion of the Consolidation).

On completion of the Consolidation, Private Placement and debt conversion, the outstanding share capital of the Company will be approximately 17,813,282 common shares (post Consolidated) on a non-diluted basis.

James Passin, Chairman, stated, "It is an honor to welcome legendary cryptocurrency pioneer, Jeremy Gardner, and accomplished technology entrepreneur and professional investment manager, Wayne Lloyd, to the Board of Directors. With the closing of the debt settlements and private placement, the Company is now positioned to launch its new cryptocurrency/blockchain proprietary indexing business. We are excited to announce additional new future business initiatives under the Company's strengthened board and executive team. Our strategic objective is to generate returns for our shareholders by carving out a role for the Company in the exponentially expanding cryptocurrency and blockchain ecosystem."

For further information, please contact:

Alan Tam, CFO
+1 604 377-7575
alantamca@gmail.com 

Malcolm Burke
+1 604 220 2000
mpb@primarycapital.net

This press release was prepared by management of the Company, which takes full responsibility for its contents.  The  Canadian Securities Exchange  or its regulators have, in no way passed upon the merits of the proposed transaction and has neither approved or disapproved the contents of this press release.

Disclaimer for Forward-Looking Information 
Statements containing forward-looking information express, as at the date of this news release, the Company's plans, estimates, forecasts, projections, expectations, or beliefs as to future events or results and are believed to be reasonable based on information currently available to the Company. Forward-looking statements and information are based on assumptions that financing and personnel will be available when required and on reasonable terms, and all necessary regulatory approvals and shareholder approval will be obtained, none of which are assured and are subject to a number of other risks and uncertainties.

There can be no assurance that forward-looking statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking information.  

 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Khot Infrastructure Holdings, Ltd. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum